Connection

Evangelos Terpos to Thalidomide

Back to Details
This is a "connection" page, showing publications Evangelos Terpos has written about Thalidomide.
Evangelos Terpos
Connection Strength
1.165
Thalidomide
  1. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep; 97(9):1671-1682.
    View in: PubMed
    Score: 0.585
  2. Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018 06; 11(6):463-469.
    View in: PubMed
    Score: 0.147
  3. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
    View in: PubMed
    Score: 0.142
  4. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
    View in: PubMed
    Score: 0.117
  5. How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013 Oct; 88 Suppl 1:S23-35.
    View in: PubMed
    Score: 0.104
  6. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):e401-e419.
    View in: PubMed
    Score: 0.037
  7. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.